Health ❯ Healthcare ❯ Clinical Trials

Phase III Trials

ASPEN Trial DESTINY-Breast05 Trial Efficacy Studies FRESCO-2 Trial Induction Chemotherapy Interlace Trial GALAXI Trials Randomised Trials COMBI-AD Study Weight Loss Efficacy CENTERSTONE Trial Orforglipron Chemotherapy Studies DESTINY-Breast09 Trial Immunological Response BREAKWATER Trial Dietary Interventions ENPP1 Deficiency Treatments DREAMM-7 Trial Atezolizumab HIMALAYA Trial Serena-6 Trial HD21 Trial EMBER-3 Trial ASPEN Study OLIGUITO Study Aceclidine Studies Baxdrostat Study Lanifibranor Trials Eli Lilly Trials TROPION-Breast01 Trial KOMET Trial FLAURA2 Trial Durvalumab Treatment Baxdrostat Trial Results NRG Oncology Trials REMIX Trials BART Trial PROTOSTAR Study IMforte Trial TROPION-Breast02 CROWN Trial Drug Efficacy AMPLITUDE Trial ASC4FIRST Trial Survival Rates Epioxa Trials DESTINY-Breast Trials REGENCY Study evERA Trial OLYMPIA Trials MATTERHORN Trial MDMA Trials MinervaX GBS Vaccine

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Regulators limited the relaunch to one regimen because safety concerns offset strong efficacy data.

FDA Approves Gazyva for Adults With Active Lupus Nephritis

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

FDA Approves Glaukos’ Epioxa, First Epithelium-On Corneal Cross-Linking Therapy in the U.S.

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

CHMP Backs Scemblix Indication Update for Pretreated Ph+ CML in Chronic Phase

CHMP Backs Brinsupri as First EU Therapy for Non‑Cystic Fibrosis Bronchiectasis

Kailera Therapeutics Raises $600 Million to Fund Global Phase 3 of Obesity Drug

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC